Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Dynamics of Oligoclonal Hematopoiesis in Severe Aplastic Anemia Patients Undergoing Immunosuppressive Treatment: Longitudinal Somatic Mutation Analysis from the EBMT Race Trial

Blood (2024) 144 (Supplement 1): 33.

https://doi.org/10.1182/blood-2024-206632

Published: 2024

Journal Articles

Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Antonio M Risitano, Simona Iacobelli, Austin G. Kulasekararaj, Marleen Van Os, Sophie Terwel, Morag Griffin, Constantijn J.M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Carlos Vallejo, Beatrice Drexler, Jean-Baptiste Méar, Alexander Smith, Emanuele Angelucci, Reinier Raymakers, Marco R De Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H. Russell, Louis Terriou, Anna Paola Iori, Walter Barberi, Anna Sureda Balari, Isabel Sanchez-Ortega, Blanca Xicoy, Isidro Jarque Ramos, Jamie Cavenagh, Flore Sicre De Fontbrune, Camilla Frieri, Talha Munir, Jennifer Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Serena Marotta, Fabiana Cacace, Marica Laurino, Jakob Passweg, Sr., Judith Marsh, Gerard Socie, Ghulam Mufti, Carlo Dufour, Regis Peffault De Latour

Blood (2024) 144 (Supplement 1): 302.

https://doi.org/10.1182/blood-2024-194699

Published: 2024

Journal Articles

Transplant Outcomes for Acute Myeloid Leukemia or Myelodysplastic Syndromes Secondary to Acquired Aplastic Anemia or Paroxysmal Nocturnal Hemoglobinuria: A Report from the EBMT Severe Aplastic Anemia Working Party

Blood (2023) 142 (Supplement 1): 704.

https://doi.org/10.1182/blood-2023-184783

Published: 2023

Journal Articles

Atgam Efficacy and Safety in Moderate-to-Very Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults from the French Authorization for Temporary Use Surveillance Program

Flore Sicre De Fontbrune, Mony Fahd, Édouard Forcade, Suzanne Tavitian, Cécile Moluçon Chabrot, Fiorenza Barraco, Yosr Hicheri, Delphine Lebon, Sébastien Maury, Anne-Lise Menard, Barbara Możejko-Pastewka, Kevin D Wolter, Bruno Valtier, Thierry Leblanc, Regis Peffault De Latour

Blood (2023) 142 (Supplement 1): 1347.

https://doi.org/10.1182/blood-2023-186493

Published: 2023

Journal Articles

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Blood (2022) 140 (Supplement 1): 6847–6849.

https://doi.org/10.1182/blood-2022-156632

Published: 2022

Journal Articles

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

Jean-Jacques Kiladjian, Jean-Christophe Ianotto, Juliette Soret, Nabih Maslah, Cendrine Chaffaut, Françoise Boyer perrard, Fiorenza Barraco, Viviane Dubruille, Claude Capron, Amandine Tisserand, Valérie Rolland-Neyret, Zineb Ghrieb, Sylvie Chevret, Isabelle Plo, Marie-Hélène Schlageter, Veronique Meignin, Matthieu Resche-Rigon, Bruno Cassinat

Blood (2022) 140 (Supplement 1): 577–578.

https://doi.org/10.1182/blood-2022-156389

Published: 2022

Journal Articles

Correlation of Clonal Hematopoiesis in Vexas Syndrome with Immunophenotype Alterations in CD34+ HSPCs (Hematopoietic Stem Progenitors Cells): Multiparametric Flow Cytometry Heterogeneity in CD34+CD38- Stem Cells Fraction and Upregulation of CD90 Thy-1 By Unsupervised Strategy Using PCA, Tsnee and Flowsom

Adriana Plesa, Joris Gutrin, Christophe Roumier, Sandrine Hayette, Isabelle Tigaud, Sarah Huet, Delphine Manzoni, Florent Dumezy, Fiorenza Barraco, Herve Ghesquieres, Claude Preudhomme, Pierre Sujobert, Mael Heiblig

Blood (2022) 140 (Supplement 1): 4086–4087.

https://doi.org/10.1182/blood-2022-169959

Published: 2022

Journal Articles

Long-Term Persistence of Mixed Full Donor Chimerism after Double Cord Blood Transplantation. Example of Tolerance in Allogeneic Hematopoietic Cell Transplantation Setting

Carole Saison, Virginie Mathias, Marie Balsat, Fiorenza Barraco, Sophie Ducastelle, Catherine Giannoli, Hélène Labussière-Wallet, Dan Adrian Luscalov, Philippe Moskovtchenko, Valerie Dubois, Mauricette Michallet

Blood (2022) 140 (Supplement 1): 12861–12862.

https://doi.org/10.1182/blood-2022-159961

Published: 2022

Journal Articles

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Blood (2022) 140 (8): 927–931.

https://doi.org/10.1182/blood.2022016642

Published: 2022

Includes: Supplemental data

Journal Articles

Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study

Blood (2021) 138 (Supplement 1): 2608.

https://doi.org/10.1182/blood-2021-150394

Published: 2021

Journal Articles

Therapeutic options in VEXAS syndrome: insights from a retrospective series

Estelle Bourbon, Maël Heiblig, Mathieu Gerfaud Valentin, Thomas Barba, Cécile-Audrey Durel, Jean Christophe Lega, Fiorenza Barraco, Pascal Sève, Yvan Jamilloux, Pierre Sujobert

Blood (2021) 137 (26): 3682–3684.

https://doi.org/10.1182/blood.2020010177

Published: 2021

Includes: Supplemental data

Journal Articles

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Paola Guglielmelli, MD, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Ming-hui Duan, MD, Haitao Meng, MD PhD, Ling Pan, MD PhD, Guangsheng He, MD PhD, Srdan Verstovsek, MD PhD, Françoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Dietger Niederwieser, MD PhD, Anna Marina Liberati, MD, Claire Harrison, DM, FRCP, FRCPath, Pantelia Roussou, MSc, Monika Wroclawska, MD, Kevin Majidi, Peter AW te Boekhorst, MD PhD, Heinz Gisslinger, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137742

Published: 2020

Journal Articles

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141890

Published: 2020

Journal Articles

Aplastic Anemia in the Elderly: A Nationwide Survey on Behalf of the French Reference Center for Aplastic Anemia

Blood (2018) 132 (Supplement 1): 1298.

https://doi.org/10.1182/blood-2018-99-113359

Published: 2018

Journal Articles

Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, Juliette Soret-Dulphy, MD, Matthieu Resche-Rigon, MD PhD, Francoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Valérie Rolland-Neyret, Claude Capron, Sylvie Chevret, MD PhD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD

Blood (2018) 132 (Supplement 1): 581.

https://doi.org/10.1182/blood-2018-99-110785

Published: 2018

Journal Articles

Viral Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: Benefits and Risks for Disease Relapse

Sandrine Loron, MD, Mohamad Sobh, PharmD, Fiorenza Barraco, MD, Xavier Thomas, MD, Sophie Ducastelle, MD, Myriam Renault, CRA, Florence Ader, MD, Emilie Frobert, MD, Franck-Emmanuel Nicolini, MD PhD, Hélène Labussière, MD, Mauricette Michallet, MD PhD

Blood (2018) 132 (Supplement 1): 2140.

https://doi.org/10.1182/blood-2018-99-118249

Published: 2018

Journal Articles

Current IST-Free/Relapse-Free Survival As a Surrogate Estimate of OS after Allotransplant for Acute Leukemia

Roberto Crocchiolo, MD PhD, Alessio Signori, Mohamad Sobh, Hélène Labussière, Myriam Renault, Fiorenza Barraco, MD, Franck Emmanuel Nicolini, MD PhD, Mauricette Michallet, MD PhD

Blood (2017) 130 (Supplement 1): 2047.

https://doi.org/10.1182/blood.V130.Suppl_1.2047.2047

Published: 2017

Journal Articles

Long-Term Outcome of Patients Receiving Extracorporeal Photopheresis for Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies: Results from an Observational Study on 106 Patients

Mauricette Michallet, MD PhD, Mohamad Sobh, Alexandre Deloire, CRA, Daniela Revesz, MD, Youcef Chelgoum, MD, Mohamed El-Hamri, CRA, Fiorenza Barraco, MD, Helene Labussiere-Wallet, MD, Franck Emmanuel Nicolini, MD PhD, Olivier Hequet, MD

Blood (2017) 130 (Supplement 1): 4504.

https://doi.org/10.1182/blood.V130.Suppl_1.4504.4504

Published: 2017

Journal Articles

Liver Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Descriptive Longitudinal Study Using Liver Parameters Monitoring and Their Impact on Transplantation Outcomes Using a Prediction Score

Mauricette Michallet, MD PhD, Mohamad Sobh, Alexandre Deloire, CRA, Ali El-Kassir, PharmD, Emilie Frobert, MD, Marie-Odile Geay-Baillat, MD, Valerie Hervieu, MD, Christophe Nougier, MD, Fiorenza Barraco, MD, Helene Labussiere, MD, Christine Lombard, MD, Franck Emmanuel Nicolini, MD PhD

Blood (2017) 130 (Supplement 1): 3236.

https://doi.org/10.1182/blood.V130.Suppl_1.3236.3236

Published: 2017

Journal Articles

Epstein-Barr Virus (EBV) Reactivation, Its Treatment with Rituximab and Their Impact on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Florence Ranchon, PharmD, Sandrine Leroy, MD, Fiorenza Barraco, MD, Xavier Thomas, MD PhD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle, MD, Bruno Lina, MD PhD, Florence Morfin, MD, Myriam Renault, CRA, Florence Ader, MD, Catherine Rioufol, PharmD, Helene Labussiere, MD, Franck-Emmanuel Nicolini, MD PhD

Blood (2016) 128 (22): 3695.

https://doi.org/10.1182/blood.V128.22.3695.3695

Published: 2016

NARROW

Dynamics of Oligoclonal Hematopoiesis in Severe Aplastic Anemia Patients Undergoing Immunosuppressive Treatment: Longitudinal Somatic Mutation Analysis from the EBMT Race Trial

Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Transplant Outcomes for Acute Myeloid Leukemia or Myelodysplastic Syndromes Secondary to Acquired Aplastic Anemia or Paroxysmal Nocturnal Hemoglobinuria: A Report from the EBMT Severe Aplastic Anemia Working Party

Atgam Efficacy and Safety in Moderate-to-Very Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults from the French Authorization for Temporary Use Surveillance Program

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

Long-Term Persistence of Mixed Full Donor Chimerism after Double Cord Blood Transplantation. Example of Tolerance in Allogeneic Hematopoietic Cell Transplantation Setting

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study

Therapeutic options in VEXAS syndrome: insights from a retrospective series

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

Aplastic Anemia in the Elderly: A Nationwide Survey on Behalf of the French Reference Center for Aplastic Anemia

Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis

Viral Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: Benefits and Risks for Disease Relapse

Current IST-Free/Relapse-Free Survival As a Surrogate Estimate of OS after Allotransplant for Acute Leukemia

Long-Term Outcome of Patients Receiving Extracorporeal Photopheresis for Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies: Results from an Observational Study on 106 Patients

Liver Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Descriptive Longitudinal Study Using Liver Parameters Monitoring and Their Impact on Transplantation Outcomes Using a Prediction Score

Epstein-Barr Virus (EBV) Reactivation, Its Treatment with Rituximab and Their Impact on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only